Charles River Laboratories International, Inc. leadership

Mr. Foster joined Charles River in 1976 as General Counsel and held various staff and managerial positions over his tenure; he was named President in 1991, Chief Executive Officer in 1992, and Chair in 2000. He has been a director since 1989, and concurrent with the 2026 Annual Meeting he intends to retire as CEO and Chair while remaining a non-executive director. He was selected to serve on the Board due to his long tenure as CEO, his depth of knowledge of the company's operations, his business judgment, and his extensive familiarity with the businesses in which the company competes.

Dr. Andrews has served as Executive Vice President and Chief Scientific Officer at Boston Children's Hospital since December 2021 and as Professor in Residence at Harvard Medical School since November 2023, and previously served as Dean of the Duke University School of Medicine and Vice Chancellor for Academic Affairs at Duke. She is an elected member of the American Academy of Arts and Sciences, the National Academy of Medicine, and the National Academy of Sciences, and serves on the boards of Novartis International AG and Maze Therapeutics. She has been a director since February 2020 and was selected for the Board for her perspective as an accomplished physician, scientific researcher, and senior academic administrator with expertise in oncology, genetics, and pediatric research.

Mr. Barg is Global Co-Head of Engagement at Elliott Investment Management L.P., which he joined in February 2020 after 30 years in investment banking, most recently as a Participating Managing Director at Goldman Sachs where he established the firm's Global Activism and Shareholder Advisory practice. He previously served on the boards of Cardinal Health and Catalent. He has been a director since May 2025, and his qualifications include significant M&A and capital markets expertise as well as public board experience in the CDMO/CRO space.

Mr. Ceesay is Chief Executive Officer of Rapport Therapeutics and previously served as President of Cerevel Therapeutics and CEO of Tiburio Therapeutics, along with executive roles at scPharmaceuticals, Keryx Biopharmaceuticals, Ironwood Pharmaceuticals, and Sanofi/Genzyme. He serves on the boards of Rapport Therapeutics, Pacira Biosciences, and Life Science Cares. He has been a director since May 2025, and his qualifications include nearly two decades of executive and public-company biopharmaceutical industry experience.

Mr. Enyedy was President and Chief Executive Officer of ImmunoGen from 2016 until its acquisition by AbbVie in 2024, and previously served as EVP and Head of Corporate Development at Shire plc and CEO of Proteostasis Therapeutics following 15 years at Genzyme Corporation. He currently serves on the boards of Astellas Pharma, BioMarin, and Ergomed plc. He has been a director since May 2025, and his qualifications include more than three decades of general management, business development, and legal experience in the biotechnology industry.

Mr. Graves was Chief Executive Officer of Rio Tinto Lithium (previously Arcadium Lithium until its March 2025 acquisition by Rio Tinto) and previously served as CEO of Livent Corporation and as EVP and Chief Financial Officer of FMC Corporation, after being a partner at Goldman Sachs. He served on the boards of Arcadium Lithium, Livent, and Lydall, Inc. He has been a director since May 2025, qualifies as an audit committee financial expert under SEC guidelines, and brings significant executive leadership, public-company board, investment banking, and M&A expertise.

Ms. Kemps-Polanco is Executive Vice President and Chief Commercial Officer of Novartis US, responsible for end-to-end commercialization across four therapeutic areas, having returned to Novartis in 2021 as EVP and US Head of Novartis Oncology. She previously held leadership positions at Johnson & Johnson from 2014 to 2021, most recently as President of Janssen U.S. Cardiovascular & Metabolism. She has been a board member since January 2024 and was selected for her extensive healthcare business leadership, deep industry experience, and over 25 years in the life-sciences sector.

Mr. Llado is the former Senior Vice President and Chief Information Officer of Alexion Pharmaceuticals, with over 30 years of pharmaceutical business, technology, and cybersecurity experience, and previously served as Vice President and business-line CIO at Merck and Co., where he led the IT integration of Merck and Schering-Plough. He serves on the boards of TraceLink Inc. and the National Center for Women & Information Technology. He has been a director since October 2020 and was selected for his experience as a senior executive at global pharmaceutical companies and his technology and cybersecurity expertise.

Dr. Mackay is co-founder, former CEO (2018-2023), former Executive Chair (2023-2024), and current Non-Executive Chair of Rallybio Corporation, and previously served as Global Head of Research & Development at Alexion Pharmaceuticals and as President of R&D at AstraZeneca PLC. He has served on the boards of Novo Nordisk and SpringWorks Therapeutics and is Charles River's Lead Independent Director. He has been a director of the company since July 2017, and his extensive experience leading R&D organizations at global pharmaceutical and biotechnology companies provides the Board a unique combination of expertise.

Dr. Thompson was President and Chief Executive Officer of Memorial Sloan-Kettering Cancer Center from 2010 to September 2022 and continues to oversee a research laboratory at the Sloan Kettering Institute focusing on cellular metabolism and its role in cancer. He is a member of the Board of Directors of Regeneron Pharmaceuticals and previously served on the board of Merck & Co. He has been a director since December 2022 and was selected for his distinct perspective as a distinguished academic and his extensive scientific and medical expertise relevant to the life-science industries.

Ms. Wilson is the retired Senior Executive Vice President and Chief Financial Officer of TIAA, where she led the finance and actuarial functions, and previously served as EVP and CFO of Wyndham Worldwide Corporation and as EVP and Chief Accounting Officer of Cendant Corporation. She is a member of the board of Carrier Global Corporation, a Certified Public Accountant, and a former public-company CFO. She has been a director since October 2019, brings more than 30 years of financial management experience, and qualifies as an audit committee financial expert under SEC guidelines.

Ms. Girshick joined Charles River in 1989 and held positions of increasing responsibility across the company's RMS Germany, Avian Vaccine, Biopharmaceutical Services, and Discovery and Safety Assessment businesses, including leading the integration of WIL Research in 2016. In November 2021 she was promoted to Chief Operating Officer, adding the Research Models and Services, Microbial Solutions, and CDMO businesses and the Global Information Technologies group, and since 2023 she has had general oversight of Corporate Sales and Marketing and Corporate and External Affairs. She will be appointed Chief Executive Officer effective May 5, 2026 and has been nominated to serve as a director.

Mr. Knell is identified in the proxy statement as one of Charles River's named executive officers for fiscal year 2025, serving as Interim Chief Financial Officer, Corporate Senior Vice President, and Chief Accounting Officer. The proxy statement does not disclose additional biographical detail or the year he assumed these roles.

Ms. Creamer is identified in the proxy statement as a named executive officer for fiscal year 2025, serving as Corporate Executive Vice President and Chief People Officer. The proxy statement does not disclose additional biographical detail or the year she assumed the role.

Mr. LaPlume is identified in the proxy statement as a named executive officer for fiscal year 2025, serving as Corporate Executive Vice President, Corporate Development & Strategy. The proxy statement does not disclose additional biographical detail or the year he assumed the role.

Ms. Pease is identified in the proxy statement as a named executive officer for fiscal year 2025, serving as former Corporate Executive Vice President and Chief Financial Officer. The proxy statement does not disclose additional biographical detail or the year she assumed or departed the role.